Publication

2019

Original Articles

• "Serum γ-glutamyltransferase as a prognostic biomarker in metastatic castration-resistant prostate cancer treated with enzalutamide"
  Kosuke Takemura, Masaya Ito, Yasukazu Nakanishi, Madoka Kataoka, Kazumasa Sakamoto, Hiroaki Suzuki, Ken-Ichi Tobisu, Fumitaka Koga.
  Anticancer Res. 39, 10, 5773-5780 (2019).

  • DOI: 10.21873/anticanres.13780
• "Multifocal synchronous upper urinary tract carcinosarcoma (sarcomatoid carcinoma) with rhabdomyoblastic differentiation"
  Kosuke Takemura, Toru Motoi, Akiko Tonooka, Nobuaki Funata, Yasukazu Nakanishi, Madoka Kataoka, Masaya Ito, Kazumasa Sakamoto, Hiroaki Suzuki, Ken-Ichi Tobisu, Fumitaka Koga.
  Int J Surg Pathol. 27, 5, 547-552 (2019).

  • DOI: 10.1177/1066896919828111
• "Prognostic significance of serum γ-glutamyltransferase in patients with advanced urothelial carcinoma"
  Kosuke Takemura, Hiroshi Fukushima, Masaya Ito, Madoka Kataoka, Yasukazu Nakanishi, Kazumasa Sakamoto, Hiroaki Suzuki, Ken-Ichi Tobisu, Fumitaka Koga.
  Urol Oncol. 37, 2, 108-115 (2019).

  • DOI: 10.1016/j.urolonc.2018.11.002

Abstract Presentations

• "Elevated serum gamma-glutamyltransferase is an adverse prognostic factor in castration-resistant prostate cancer treated with enzalutamide"
  Kosuke Takemura, Masaya Ito, Yasukazu Nakanishi, Madoka Kataoka, Kazumasa Sakamoto, Hiroaki Suzuki, Ken-Ichi Tobisu, Fumitaka Koga.
  J Urol. 201, 4 Suppl, e407-e408 (2019).

  • DOI: 10.1097/01.JU.0000555716.12585.c0
• "Prognostic significance of serum γ-glutamyltransferase in patients with castration-resistant prostate cancer treated with enzalutamide"
  Kosuke Takemura, Masaya Ito, Yasukazu Nakanishi, Madoka Kataoka, Kazumasa Sakamoto, Hiroaki Suzuki, Ken-Ichi Tobisu, Fumitaka Koga.
  Eur Urol. 18, 1 Suppl, e145-e146 (2019).

  • DOI: 10.1016/S1569-9056(19)30111-3